A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)

Trial Profile

A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs IMAB 027 (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; First in man
  • Acronyms OVAR
  • Sponsors Ganymed Pharmaceuticals
  • Most Recent Events

    • 30 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 16 Mar 2017 Time frame of primary endpoint has changed from 5 months to 24 months.
    • 16 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top